

Our ref: IG/FOI/FOI.606.25

1 December 2025

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 28 November 2025, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require.

For ease of reference your request is set out below and the Health Board's response follows.

Your Freedom of Information (FOI) Request:

I am writing to you under the Freedom of Information Act to request the following information:

I would be grateful if you could send me information related to durvalumab (Imfinzi) and trastuzumab deruxtecan (Enhertu). Please include all hospitals in your organisation.

1. Does the aseptic unit at your organisation employ vial-sharing for durvalumab (Imfinzi)?

	Yes / No
Employs vial-sharing for durvalumab (Imfinzi)	

2. In the past 12 months was durvalumab (Imfinzi) administered as the following actual doses?

	Yes / No
1,500 mg	
10 mg / kg	
20 mg / kg	

3. In the past 12 months was durvalumab (Imfinzi) made up for administration to patients at an on-site aseptic unit?

	Yes / No
On-site aseptic unit	

4. In the past 12 months was durvalumab (Imfinzi) made up for administration to patients at an external aseptic unit?

	Yes / No
External aseptic unit – based at another hospital	
External aseptic unit – from a third supplier	

5. Please list the names of external hospitals or hospitals within the Trust that have supplied your organisation with made-up batches of durvalumab (Imfinzi) in the past 12 months.

6. How many patients were treated with durvalumab (Imfinzi) between Jul and Sep 2025, or latest 3 months for which data is available?

Number of patients

7. How many patients were treated with durvalumab (Imfinzi) within each of bands in the national dose banding table between Jul and Sep 2025?

Band range (mg)			Band dose (mg)	Number of patients
From ≥	To (A) <	To (B) ≤		
189.74	219.09	219.08	200	
219.09	268.33	268.32	240	
268.33	328.63	328.62	300	
328.63	388.84	388.83	360	
388.84	458.26	458.25	420	
458.26	547.72	547.71	500	
547.72	648.07	648.06	600	
648.07	771.36	771.35	700	
771.36	921.95	921.94	850	
921.95	1058.30	1058.29	1000	
1058.30	1178.47	1178.46	1120	
1178.47	1363.82	1363.81	1240	

1363.82	1596.87	1596.86	1500	
1596.87	1843.91	1843.90	1700	

<https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-b/b02/chemotherapy-dose-banding/>

8. How many patients were treated with durvalumab (Imfinzi) for the following types of cancer between Jul and Sep 2025, or latest 3 months for which data is available?

Type of Cancer	Number of patients
Non-small Cell Lung Cancer	
Biliary Tract Cancer	
Small Cell Lung Cancer	
Hepatocellular Carcinoma	
Endometrial Cancer	
Muscle Invasive Bladder Cancer	
Other (please specify)	

9. Does the aseptic unit employ vial-sharing for trastuzumab deruxtecan (Enhertu)?

	Yes / No
Employs vial-sharing for trastuzumab deruxtecan (Imfinzi)	

10. In the past 12 months was trastuzumab deruxtecan (Enhertu) administered as the following actual doses?

	Yes / No
6.4 mg / kg	
5.4 mg / kg	
4.4 mg / kg	
< 4.4 mg / kg	

11. In the past 12 months was trastuzumab deruxtecan (Enhertu) made up for administration to patients at an on-site aseptic unit?

	Yes / No
On-site aseptic unit	

12. In the past 12 months was trastuzumab deruxtecan (Enhertu) made up for administration to patients at an external aseptic unit?

	Yes / No
External aseptic unit – based at another hospital	
External aseptic unit – from a third supplier	

13. Please list the names of external hospitals or hospitals within the Trust that have supplied your organisation with made-up batches of trastuzumab deruxtecan (Enhertu) in the past 12 months.

14. How many patients were treated with trastuzumab deruxtecan (Enhertu) within each of bands in the national dose banding table between Jul and Sep 2025?

Band Range (mg)			Band Dose (mg)	Number of patients
From ≥	To (A) <	To (B) ≤		
95.92	103.92	103.91	100.00	
103.92	111.93	111.92	108.00	
111.93	121.85	121.84	116.00	
121.85	135.77	135.76	128.00	
135.77	151.79	151.78	144.00	
151.79	169.71	169.70	160.00	
169.71	189.74	189.73	180.00	
189.74	209.76	209.75	200.00	
209.76	229.78	229.77	220.00	
229.78	249.80	249.79	240.00	
249.80	269.82	269.81	260.00	
269.82	289.83	289.82	280.00	
289.83	309.84	309.83	300.00	
309.84	339.41	339.40	320.00	
339.41	379.47	379.46	360.00	
379.47	419.52	419.51	400.00	
419.52	459.57	459.56	440.00	
459.57	489.90	489.89	480.00	
489.90	519.62	519.61	500.00	
519.62	569.21	569.20	540.00	
569.21	619.68	619.67	600.00	
619.68	669.33	669.32	640.00	
669.33	719.72	719.71	700.00	
719.72	769.42	769.41	740.00	
769.42	848.53	848.52	800.00	
848.53	948.68	948.67	900.00	

<https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-b/b02/chemotherapy-dose-banding/>

Powys Response:

Powys Teaching Health Board (PTHB) does not have District General Hospital (DGH) services, an aseptic unit or provide systemic anti-cancer treatment services. Our residents access their acute and specialist cancer services in DGH's provided by neighbouring health boards in Wales and neighbouring NHS Trusts in England. The table below lists the main health boards and NHS Trust from which we commission health services for Powys residents. Please note that all providers may not necessarily offer services that fall within the definition in your request.

Health Trust/Organisation	FOI Contact Details
Gloucestershire Hospitals NHS Foundation Trust	ghn-tr.foi@nhs.net
Midlands Partnership University NHS Foundation Trust	FOI@mpft.nhs.uk
The Robert Jones Agnes Hunt Orthopaedic Hospital NHS Foundation Trust	rjah.foi@nhs.net
Sandwell and West Birmingham NHS Trust	swb-tr.SWBH-GM-FOIRequests@nhs.net
The Shrewsbury and Telford Hospital NHS Trust	sath.foi@nhs.net
The Royal Wolverhampton NHS Trust	rwh-tr.foi@nhs.net
Worcestershire Acute Hospitals NHS Trust	wah-tr.FOI@nhs.net
Wye Valley NHS Trust	Freedom.Information@wvt.nhs.uk

Health Board/Organisation	FOI Contact Details
Aneurin Bevan University Health Board	FOI.ABB@wales.nhs.uk
Betsi Cadwaladr University Health Board	bcu.foi@wales.nhs.uk
Cardiff & Vale University Health Board	FOI.Requests@wales.nhs.uk
Cwm Taf Morgannwg University Health Board	CTM.FreedomOfInformation@wales.nhs.uk
Hywel Dda University Health Board	FOI.hyweldda@wales.nhs.uk
Swansea Bay University Health Board	FOIA.Requests@wales.nhs.uk
Velindre University NHS Trust	Foi.vunhst@wales.nhs.uk

If you have queries or any concerns, contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications. If you are dissatisfied with the handling or response to your request and wish to ask for a review of this, please contact us and we will arrange for this to be done.

Further information is available from the Information Commissioner's Office who can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: www.ico.org.uk/foicomplaints

Web site: <https://ico.org.uk/>


Re-use of Public Sector Information

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.

Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at [Open Government Licence](#).

Yours sincerely



Kate Wright
Executive Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.